PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25590338-7	2015	Importantly, ERBB4 knockdown triggered apoptosis not only in lapatinib-resistant cells but also in trastuzumab-resistant cells.	Lapatinib	61-70	erb-b2 receptor tyrosine kinase 4	Homo sapiens	13-18	
25590338-4	2015	We demonstrate that genetic ablation of ERBB4, but not ERBB1-3, led to apoptosis in lapatinib-resistant cells, suggesting that the efficacy of pan-ERBB inhibitors was, at least in part, mediated by the inhibition of ERBB4.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 4	Homo sapiens	40-45	
25590338-4	2015	We demonstrate that genetic ablation of ERBB4, but not ERBB1-3, led to apoptosis in lapatinib-resistant cells, suggesting that the efficacy of pan-ERBB inhibitors was, at least in part, mediated by the inhibition of ERBB4.	Lapatinib	84-93	erb-b2 receptor tyrosine kinase 4	Homo sapiens	216-221	
25590338-5	2015	Moreover, ERBB4 was upregulated at the protein level in ERBB2+ breast cancer cell lines selected for acquired lapatinib resistance in vitro and in MMTV-Neu mice following prolonged lapatinib treatment.	Lapatinib	110-119	erb-b2 receptor tyrosine kinase 4	Homo sapiens	10-15	
25590338-5	2015	Moreover, ERBB4 was upregulated at the protein level in ERBB2+ breast cancer cell lines selected for acquired lapatinib resistance in vitro and in MMTV-Neu mice following prolonged lapatinib treatment.	Lapatinib	181-190	erb-b2 receptor tyrosine kinase 4	Homo sapiens	10-15	
25590338-6	2015	Knockdown of ERBB4 caused a decrease in AKT phosphorylation in resistant cells but not in sensitive cells, suggesting that ERBB4 activated the PI3K/AKT pathway in lapatinib-resistant cells.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 4	Homo sapiens	13-18	
25590338-6	2015	Knockdown of ERBB4 caused a decrease in AKT phosphorylation in resistant cells but not in sensitive cells, suggesting that ERBB4 activated the PI3K/AKT pathway in lapatinib-resistant cells.	Lapatinib	163-172	erb-b2 receptor tyrosine kinase 4	Homo sapiens	123-128	
25590338-8	2015	Our results suggest that although ERBB4 is dispensable for naive ERBB2+ breast cancer cells, it may play a key role in the survival of ERBB2+ cancer cells after they develop resistance to ERBB2 inhibitors, lapatinib and trastuzumab.	Lapatinib	206-215	erb-b2 receptor tyrosine kinase 4	Homo sapiens	34-39	
25492965-4	2014	Knocking down YAP or ERBB4 prevented the induction of CTGF expression by NRG1, as did treating cells with the ERBB inhibitors lapatinib or erlotinib, which reduced ERBB4 cleavage.	Lapatinib	126-135	erb-b2 receptor tyrosine kinase 4	Homo sapiens	164-169	
24258993-4	2014	Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.	Lapatinib	178-187	erb-b2 receptor tyrosine kinase 4	Homo sapiens	8-13	
24628946-4	2014	Mutations in melanoma cell lines correlated with their sensitivity to corresponding small molecule inhibitors, confirming, for example, lapatinib sensitivity in ERBB4 mutant lines and identifying a novel activating mutation of BRAF.	Lapatinib	136-145	erb-b2 receptor tyrosine kinase 4	Homo sapiens	161-166	
24258993-4	2014	Mutated ERBB4 signaling activates both aberrant ERBB4 and PI3K-AKT signal transduction, mediates sensitivity to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma.	Lapatinib	178-187	erb-b2 receptor tyrosine kinase 4	Homo sapiens	48-53	
24258993-8	2014	This sequencing technique has successfully been applied within a clinical trial selecting patients with ERBB4-mutant melanoma for lapatinib treatment.	Lapatinib	130-139	erb-b2 receptor tyrosine kinase 4	Homo sapiens	104-109	
19718025-6	2009	Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib.	Lapatinib	140-149	erb-b2 receptor tyrosine kinase 4	Homo sapiens	33-38	
22352796-1	2012	The dual kinase inhibitor lapatinib has a high affinity for EGFR and HER2 but a weak affinity for ErbB4, although the factors driving specificity for these highly homologous members of the ErbB family of receptor tyrosine kinases are not well understood.	Lapatinib	26-35	erb-b2 receptor tyrosine kinase 4	Homo sapiens	98-103	
34159337-5	2021	ErbB4, but not lapatinib"s cancer targets ErbB1 and ErbB2, is required for SARS-CoV-2 entry and encephalitis alphavirus infection and is a molecular target mediating lapatinib"s antiviral effect.	Lapatinib	166-175	erb-b2 receptor tyrosine kinase 4	Homo sapiens	0-5	
30023006-1	2018	Background: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro.	Lapatinib	134-143	erb-b2 receptor tyrosine kinase 4	Homo sapiens	103-108